Rethinking the effectiveness of hypomethylating agents in myelodysplastic syndromes: the 50%-2-year wall

Authors

Howard S. Oster (ORCID: https://orcid.org/0000-0003-1936-4675)
Moshe Mittelman

Institutions

Tel Aviv Sourasky Medical Center (IL)

Publication Details

Journal: Haematologica
Published: 2026-01-22
DOI: https://doi.org/10.3324/haematol.2025.300405
Primary Topic: Acute Myeloid Leukemia Research
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Rethinking the effectiveness of hypomethylating agents in myelodysplastic syndromes: the 50%-2-year wall

Howard S. Oster, Moshe Mittelman

Jan 22, 2026

Haematologica

Acute Myeloid Leukemia Research

article

Rethinking the effectiveness of hypomethylating agents in myelodysplastic syndromes: the 50%-2-year wall

Howard S. Oster, Moshe Mittelman

January 22, 2026article en

Abstract

No abstract available for this paper.

Haematologica

Tel Aviv Sourasky Medical Center (IL)

Openalex Percentile: Top 83%

Acute Myeloid Leukemia Research

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Rethinking the effectiveness of hypomethylating agents in myelodysplastic syndromes: the 50%-2-year wall — Howard S. Oster, Moshe Mittelman · Haematologica (2026) | TGRS Research Map | TGRS